Not far from where the COVID-19 pandemic originated in Wuhan, China, the Chinese medical technology company Anhui DeepBlue manufactured and distributed to the United States tens of thousands of defective antibody tests that showed false-positive results. Now, an American medical company is suing DeepBlue in an effort to recover nearly half a million dollars it lost buying defective tests.

Shane Stevens, CEO of AnyPlace MD — a nationwide mobile medical company that provides “point of care testing with real-time results” based in Austin, Texas — told American Military News that he first sought a contract to purchase DeepBlue’s tests in March 2020, but finding tests in the early days of the pandemic was “like a fight.”

Months later, Stevens was finally able to purchase 100,000 antibody tests from Anhui DeepBlue Medical Technology Co. for $600,000 on May 30, 2020.